Regeneron Pharmaceuticals, Inc. is a global leader in the discovery, invention, development, manufacturing, and commercialization of medicines to treat various diseases. Headquartered in Tarrytown, New York, the company offers a wide range of products targeting conditions such as neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity. Regeneron Pharmaceuticals provides solutions to asthma and atopic dermatitis in adults and pediatrics with Dupixent injection. The company's Libtayo injection is used to treat metastatic or locally advanced cutaneous squamous cell carcinoma while Praluent injection aids in the treatment of heterozygous familial hypercholesterolemia and clinical atherosclerotic cardiovascular disease in adults. Recently, the company developed REGEN-COV to combat the spread of COVID-19. Regeneron Pharmaceuticals also offers solutions to treat rheumatoid arthritis in adults with Kevzara solution. Moreover, the company has product candidates in development to treat patients with various diseases such as eye, allergic and inflammatory, cardiovascular and metabolic, infectious, rare diseases, cancer, pain, and hematologic conditions. Regeneron Pharmaceuticals has collaboration and license agreements with global pharmaceutical companies such as Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. Additionally, the company has an agreement with the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company, which was formed in 1988, continues to grow and innovate to provide solutions for patients worldwide.